Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    IRLAB Therapeutics

    MCap

    SEK653m

    Last close

    SEK14.10

    ▲ 1.50 (11.90%)

    VolitionRx

    MCap

    USD51m

    Last close

    USD0.60

    ▲ 0.05 (9.82%)

    Portobello SpA

    MCap

    EUR12m

    Last close

    EUR2.38

    ▲ 0.20 (9.17%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

OpGen: Edison Open House Healthcare 2022

OpGen: Edison Open House Healthcare 2022

OpGen — 5 videos in collection

More on this equity

OpGen is focused on revolutionizing the identification and treatment of bacterial infections. Following the merger with Curetis, it has technology to detect pathogens and predict resistance. Importantly, the AMR Gene Panel and Unyvero platforms have the ability to provide results in hours instead of days.

• Tell us about OpGen’s focus on and approach to antimicrobial resistance.
• Please describe your licensing strategy for Ares Genetics.
• How large do you anticipate the unmet need in the genomic sequencing market to be?
• Which milestones should investors focus on in the coming year?

< Previous
Next >

You may also be interested in these:

Healthcare

OpGen: Encouraging top-line data from Unyvero urinary tract infection (UTI) panel

Healthcare

OpGen Webinar – A corporate and business update from the front lines of the fight against AMR

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free